Outcomes of Tocilizumab and Sarilumab for Hospitalized Patients with COVID-19: Retrospective Study

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in previous studies. However, more data are needed to emphasize these studies; Objectives The aim of this work was to study the outcomes of TZ and SL for hospitalized patients with COVID-19; Patients and Methods This retrospective study was carried out at Specialized Ain Shams University Obour Hospital on 100 severe or critically ill hospitalized COVID-19 patients; Results In critically ill patients with Covid-19, the interleukin-6 receptor antagonists tocilizumab and sarilumab were both effective as compared with the current standard of care, which included glucocorticoids in the majority of patients (>80%). The benefit was consistent across primary and secondary outcomes and across subgroups and secondary analyses; Conclusion In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than sarilumab at 28 days. In which administration of either tocilizumab or sarilumab was associated with improve clinical and laboratory outcome compared. The association is not dependent on the choice of interleukin-6 receptor antagonist.